A Case of Interstitial Lung Disease Probably Related to Rituximab Treatment
Tóm tắt
A 44-year-old male developed interstitial lung disease (ILD) during treatment with rituximab (375 mg/m2 weekly intravenous × 4 weeks) for the management of immune thrombocytopenia (ITP). After 1 month of treatment he developed dyspnea, fever (38.9 °C), an increase of C-reactive protein (CRP) and white blood cells with hypoxemia, and decreased platelets. Chest X-ray and high-resolution computed tomography revealed diffuse bilateral lung infiltrates. He was diagnosed with severe ILD; rituximab was discontinued, and treatment with fluticasone combined with salmeterol, methylprednisolone, and omeprazole was started, with an improvement of symptoms over 15 days with normalization in CRP at 30 days. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient’s symptoms and the suspect drug. In conclusion, in ITP patients treated with rituximab, we suggest evaluating pulmonary endpoints through pharmaco-epidemiological observational studies.
Tài liệu tham khảo
Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133(4):364–74. doi:10.1111/j.1365-2141.2006.06024.x (Epub 2006/04/29).
Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010;85(3):174–80. doi:10.1002/ajh.21616 (Epub 2010/02/05).
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207. doi:10.1182/blood-2010-08-302984 (Epub 2011/02/18).
Lu KH, George JN, Vesely SK, Terrell DR. Management of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologists. The Am J Med Sci. 2014;347(3):190–4. doi:10.1097/MAJ.0b013e31827f4dd1 (Epub 2013/03/07).
Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin N Am. 2004;30(2):393–403, viii. doi:10.1016/j.rdc.2004.01.006 (Epub 2004/06/03).
Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–81. doi:10.1056/NEJMoa032534 (Epub 2004/06/18).
Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther. 2007;20(4):277–87. doi:10.1111/j.1529-8019.2007.00141.x (Epub 2007/11/01).
Carr DR, Heffernan MP. Innovative uses of rituximab in dermatology. Dermatol Clin. 2010;28(3):547–57. doi:10.1016/j.det.2010.03.002 (Epub 2010/06/01).
Danes I, Agusti A, Vallano A, et al. Outcomes of off-label drug uses in hospitals: a multicentric prospective study. Eur J Clin Pharmacol. 2014;70(11):1385–93. doi:10.1007/s00228-014-1746-2 (Epub 2014/09/10).
Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51(4):653–62. doi:10.1093/rheumatology/ker290 (Epub 2011/12/14).
Child N, O’Carroll M, Berkahn L. Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura. Intern Med J. 2012;42(3):e12–4. doi:10.1111/j.1445-5994.2011.02701.x (Epub 2012/03/22).
Kong H, Wang Y, Zeng X, Zhu Q, Xie W, Dai S. Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report. J Clin Pharm Ther. 2014;39(6):691–4. doi:10.1111/jcpt.12198 (Epub 2014/08/19).
Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Resp Int Rev Thorac Dis. 2008;76(4):449–53. doi:10.1159/000104866 (Epub 2007/06/29).
Gonzalez V, Salgueiro E, Jimeno FJ, Hidalgo A, Rubio T, Manso G. Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab. Pharmacoepidemiol Drug Saf. 2008;17(7):714–21. doi:10.1002/pds.1587 (Epub 2008/03/15).
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. doi:10.1038/clpt.1981.154 (Epub 1981/08/01).
Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Resp Med J. 2012;6:63–74. doi:10.2174/1874306401206010063 (Epub 2012/08/17).
Lopez P, Kohler S, Dimri S. Interstitial Lung Disease Associated with mTOR inhibitors in solid organ transplant recipients: results from a large phase III clinical trial program of everolimus and review of the literature. J Transpl. 2014;2014:305931. doi:10.1155/2014/305931 (Epub 2015/01/13).
Casanova MJ, Chaparro M, Valenzuela C, Cisneros C, Gisbert JP. Adalimumab-induced interstitial pneumonia in a patient with Crohn’s disease. World J Gastroenterol WJG. 2015;21(7):2260–2. doi:10.3748/wjg.v21.i7.2260 (Epub 2015/02/27).
Fontana V, Horstman LL, Donna E, Dudkiewicz P, Ahn ER, Ahn YS. Interstitial lung disease (ILD) and severe ITP. Hematology. 2007;12(1):75–80. doi:10.1080/10245330600938281 (Epub 2007/03/17).
Gallelli L, Galasso O, Urzino A, et al. Characteristics and clinical implications of the pharmacokinetic profile of ibuprofen in patients with knee osteoarthritis. Clin Drug Investig. 2012;32(12):827–33. doi:10.1007/s40261-012-0011-7 (Epub 2012/10/23).
Gareri P, De Fazio P, Gallelli L, et al. Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Ann Pharmacother. 2008;42(3):434–8. doi:10.1345/aph.1K405 (Epub 2008/02/28).
Mumoli L, Gambardella A, Labate A, et al. Rosacea-like facial rash related to metformin administration in a young woman. BMC Pharmacol Toxicol. 2014;15:3. doi:10.1186/2050-6511-15-3 (Epub 2014/02/11).
De Vuono A, Palleria C, Scicchitano F, Squillace A, De Sarro G, Gallelli L. Skin rash during treatment with generic itraconazole. J Pharmacol Pharmacother. 2014;5(2):158–60. doi:10.4103/0976-500X.130086 (Epub 2014/05/07).
Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: Serious adverse events associated with the use of rituximab—a critical care perspective. Crit Care. 2012;16(4):231. doi:10.1186/cc11304 (Epub 2012/09/13).
Sumida H, Asano Y, Tamaki Z, et al. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol. 2014;41(5):418–20. doi:10.1111/1346-8138.12461 (Epub 2014/05/08).
Moazedi-Fuerst FC, Kielhauser SM, Brickmann K, et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol. 2014;43(3):257–8. doi:10.3109/03009742.2013.869617 (Epub 2014/03/13).
Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66(5):700–3. doi:10.1136/ard.2006.060772 (Epub 2006/10/17).
Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J Off J Eur Haematol Assoc EHA. 2001;2(6):378–84. doi:10.1038/sj/thj/6200133 (Epub 2002/03/29).
Gallelli L, Pelaia G, D’Agostino B, et al. Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ET(A) receptor-dependent activation of MAP kinases. J Cell Biochem. 2005;96(4):858–68. doi:10.1002/jcb.20608 (Epub 2005/09/09).
Gallelli L, Pelaia G, Fratto D, et al. Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells. Int J Immunopathol Pharmacol. 2010;23(2):471–9 (Epub 2010/07/22).
Pelaia G, Gallelli L, D’Agostino B, et al. Effects of TGF-beta and glucocorticoids on map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts. J Cell Physiol. 2007;210(2):489–97. doi:10.1002/jcp.20884 (Epub 2006/10/18).
Caccaro R, Savarino E, D’Inca R, Sturniolo GC. Noninfectious interstitial lung disease during infliximab therapy: case report and literature review. World J Gastroenterol WJG. 2013;19(32):5377–80. doi:10.3748/wjg.v19.i32.5377 (Epub 2013/08/29).
Dias OM, Pereira DA, Baldi BG, et al. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. Journal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2014;40(1):77–81. doi:10.1590/S1806-37132014000100012 (Epub 2014/03/15).
Leger S, Etienne M, Duval-Modeste AB, Roussel A, Caron F, Thiberville L. Interstitial pneumonia after infliximab therapy for psoriasis. Ann Dermatol Venereol. 2011;138(6–7):499–503. doi:10.1016/j.annder.2011.01.043 (Epub 2011/06/28).
Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol. 2012;39(2):289–93. doi:10.1111/j.1600-0560.2011.01795.x (Epub 2011/09/09).
De Nardo D, De Nardo CM, Latz E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am J Pathol. 2014;184(1):42–54. doi:10.1016/j.ajpath.2013.09.007 (Epub 2013/11/05).
Protopapadakis C, Antoniou KM, Voloudaki A, et al. Rituximab-induced nonspecific interstitial pneumonia like reaction in a patient with idiopathic thrombocytopenic purpura. Respir Med CME. 2009;2:176–8.